Cagri-Sema

Cagrisema is a combination of peptides that includes Semaglutide and Cagrilintide, being developed as a potential treatment for type 2 diabetes and obesity. Semaglutide is a GLP-1 agonist that stimulates insulin production, while Cagrilintide is a dual amylin and calcitonin receptor agonist that promotes feelings of fullness.

Benefits:

Weight Loss: CagriSema has shown remarkable outcomes in weight reduction. Preliminary studies saw an average weight loss of 15.6%.

Improved Glycemic Control: CagriSema has shown to significantly improve A1C levels, a key marker for blood sugar control.

Increased Time in Range: Time in range refers to the percentage of time that a person’s blood glucose levels are within the target range.

Please be aware that products found on our website come in a lyophilized powder form and will require reconstitution. Reconstitution involves adding a suitable solvent to reach the desired concentration for your experiments. We do not offer any guidance or recommendations for research protocols.

Please ensure that you are aware of our Terms and Conditions before making a purchase, as this product is intended solely for laboratory research purposes and should not be used for human consumption, medical, or veterinary purposes.